Chapter 1 Biosimilar Monoclonal Antibodies (mAbs) Market Overview
1.1 Biosimilar Monoclonal Antibodies (mAbs) Definition
1.2 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Status and Outlook (2018-2032)
1.3 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Comparison by Region (2018-2032)
1.4 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Comparison by Type (2018-2032)
1.5 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Comparison by Application (2018-2032)
1.6 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size Comparison by Sales Channel (2018-2032)
1.7 Biosimilar Monoclonal Antibodies (mAbs) Market Dynamics
1.7.1 Market Drivers/Opportunities
1.7.2 Market Challenges/Risks
1.7.3 Market News (Merger/Acquisition/Expansion)
1.7.4 Key Trends in Biosimilar Monoclonal Antibodies (mAbs) Market
Chapter 2 Biosimilar Monoclonal Antibodies (mAbs) Market Competition by Player
2.1 Global Biosimilar Monoclonal Antibodies (mAbs) Sales and Market Share by Player (2021-2023)
2.2 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Player (2021-2023)
2.3 Global Biosimilar Monoclonal Antibodies (mAbs) Average Price by Player (2021-2023)
2.4 Players Competition Situation & Trends
2.5 Conclusion of Segment by Player
Chapter 3 Biosimilar Monoclonal Antibodies (mAbs) Market Segment by Type
3.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market by Type
3.1.1 Infliximab
3.1.2 Rituximab
3.1.3 Trastuzumab
3.1.4 Adalimumab
3.1.5 Others
3.2 Global Biosimilar Monoclonal Antibodies (mAbs) Sales and Market Share by Type (2018-2023)
3.3 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Type (2018-2023)
3.4 Global Biosimilar Monoclonal Antibodies (mAbs) Average Price by Type (2018-2023)
3.5 Conclusion of Segment by Type
Chapter 4 Biosimilar Monoclonal Antibodies (mAbs) Market Segment by Application
4.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market by Application
4.1.1 Oncology
4.1.2 Autoimmune Disease
4.1.3 Others
4.2 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Application (2018-2023)
4.3 Conclusion of Segment by Application
Chapter 5 Biosimilar Monoclonal Antibodies (mAbs) Market Segment by Sales Channel
5.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market by Sales Channel
5.1.1 Direct Channel
5.1.2 Distribution Channel
5.2 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Sales Channel (2018-2023)
5.3 Conclusion of Segment by Sales Channel
Chapter 6 Biosimilar Monoclonal Antibodies (mAbs) Market Segment by Region & Country
6.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR by Region (2018-2032)
6.2 Global Biosimilar Monoclonal Antibodies (mAbs) Sales and Market Share by Region (2018-2023)
6.3 Global Biosimilar Monoclonal Antibodies (mAbs) Revenue and Market Share by Region (2018-2023)
6.4 North America
6.4.1 North America Market by Country
6.4.2 North America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.4.3 North America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.4.4 United States
6.4.5 Canada
6.5 Europe
6.5.1 Europe Market by Country
6.5.2 Europe Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.5.3 Europe Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.5.4 Germany
6.5.5 UK
6.5.6 France
6.5.7 Italy
6.5.8 Spain
6.5.9 Russia
6.6 Asia-Pacific
6.6.1 Asia-Pacific Market by Country
6.6.2 Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.6.3 Asia-Pacific Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.6.4 China
6.6.5 Japan
6.6.6 Korea
6.6.7 India
6.6.8 Southeast Asia
6.6.9 Australia
6.7 South America
6.7.1 South America Market by Country
6.7.2 South America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.7.3 South America Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.7.4 Brazil
6.7.5 Mexico
6.7.6 Argentina
6.7.7 Colombia
6.8 Middle East & Africa
6.8.1 Middle East & Africa Market by Country
6.8.2 Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Market Share by Type
6.8.3 Middle East & Africa Biosimilar Monoclonal Antibodies (mAbs) Market Share by Application
6.8.4 Turkey
6.8.5 UAE
6.8.6 Saudi Arabia
6.8.7 South Africa
6.9 Conclusion of Segment by Region
Chapter 7 Profile of Leading Biosimilar Monoclonal Antibodies (mAbs) Players
7.1 Celltrion
7.1.1 Company Snapshot
7.1.2 Product/Service Offered
7.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)
7.2 Pfizer (Hospira)
7.3 3SBIO
7.4 Novartis (Sandoz)
7.5 Dr Reddy?s
7.6 Celgen Biopharma
7.7 Cadila Healthcare
7.8 Hisun Pharma
7.9 Torrent Pharmaceuticals
7.10 Biocon
Chapter 8 Upstream and Downstream Analysis of Biosimilar Monoclonal Antibodies (mAbs)
8.1 Industrial Chain of Biosimilar Monoclonal Antibodies (mAbs)
8.2 Upstream of Biosimilar Monoclonal Antibodies (mAbs)
8.3 Downstream of Biosimilar Monoclonal Antibodies (mAbs)
Chapter 9 Development Trend of Biosimilar Monoclonal Antibodies (mAbs) (2024-2032)
9.1 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size (Sales and Revenue) Forecast (2024-2032)
9.2 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Region (2024-2032)
9.3 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Type (2024-2032)
9.4 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Application (2024-2032)
9.5 Global Biosimilar Monoclonal Antibodies (mAbs) Market Size and CAGR Forecast by Sales Channel (2024-2032)
Chapter 10 Appendix
10.1 Research Methodology
10.2 Data Sources
10.3 Disclaimer
10.4 Analysts Certification
